| pubmed-article:12691153 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12691153 | lifeskim:mentions | umls-concept:C0024299 | lld:lifeskim |
| pubmed-article:12691153 | lifeskim:mentions | umls-concept:C1514821 | lld:lifeskim |
| pubmed-article:12691153 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:12691153 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:12691153 | pubmed:dateCreated | 2003-4-14 | lld:pubmed |
| pubmed-article:12691153 | pubmed:abstractText | The association of Non-Hodgkin Lymphoma (NHL) and HIV-infection was soon recognized and the Center of Disease Control (CDC) has classified some types of NHL as AIDS-defining illnesses (ADI). Hodgkin's disease (HD) represents the most common type of non ADI malignancy in HIV-infected cases. Commonly, data on malignant lymphoma in this population is collected in known HIV-positive patients or in autopsy-series. This registration study was designed to estimate the incidence of HIV-positivity in patients with newly diagnosed malignant lymphoma. A registration of all patients with newly diagnosed malignant lymphoma and their HIV-status was performed in every center of the Swiss Group for Clinical Cancer research (SAKK) from January 1, 1991 to July 31, 1993. Among 474 eligible patients, HIV-status was evaluated in 400 and 52 were tested positive (13%), 42 (81%) of them males. Three of them were newly detected cases (after lymphoma-diagnosis). Three hundred and forty patients (72%) presented with NHL, 42 (12.4%) of them HIV-positive; 33 out of these had aggressive lymphoma. B-symptoms were significantly more frequent in HIV-positive patients. In the 134 patients with HD, 10 (7.5%) tested HIV-positive, mostly presenting with stage IV disease (7), B-symptoms (9) and extranodal disease (7). In conclusion, 13% out of 400 evaluated patients with newly diagnosed malignant lymphoma tested HIV-positive. The study confirms the predominance of aggressive lymphoma histologies and frequent presentation with B-symptoms in HIV-positive patients with NHL. Male gender, young age (26-35 years) and B-symptoms are prognostic factors for HIV-positivity in NHL. | lld:pubmed |
| pubmed-article:12691153 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12691153 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12691153 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12691153 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12691153 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:12691153 | pubmed:issn | 1042-8194 | lld:pubmed |
| pubmed-article:12691153 | pubmed:author | pubmed-author:KettererNicol... | lld:pubmed |
| pubmed-article:12691153 | pubmed:author | pubmed-author:TorhorstJoach... | lld:pubmed |
| pubmed-article:12691153 | pubmed:author | pubmed-author:CavalliFranco... | lld:pubmed |
| pubmed-article:12691153 | pubmed:author | pubmed-author:LohriAndreasA | lld:pubmed |
| pubmed-article:12691153 | pubmed:author | pubmed-author:CernyThomasT | lld:pubmed |
| pubmed-article:12691153 | pubmed:author | pubmed-author:MaibachRudolf... | lld:pubmed |
| pubmed-article:12691153 | pubmed:author | pubmed-author:StahelRolfR | lld:pubmed |
| pubmed-article:12691153 | pubmed:author | pubmed-author:D'AddarioGian... | lld:pubmed |
| pubmed-article:12691153 | pubmed:author | pubmed-author:DieterleAlexa... | lld:pubmed |
| pubmed-article:12691153 | pubmed:author | pubmed-author:EgliFritzF | lld:pubmed |
| pubmed-article:12691153 | pubmed:author | pubmed-author:FeyMartinM | lld:pubmed |
| pubmed-article:12691153 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12691153 | pubmed:volume | 44 | lld:pubmed |
| pubmed-article:12691153 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12691153 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12691153 | pubmed:pagination | 133-8 | lld:pubmed |
| pubmed-article:12691153 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:12691153 | pubmed:meshHeading | pubmed-meshheading:12691153... | lld:pubmed |
| pubmed-article:12691153 | pubmed:meshHeading | pubmed-meshheading:12691153... | lld:pubmed |
| pubmed-article:12691153 | pubmed:meshHeading | pubmed-meshheading:12691153... | lld:pubmed |
| pubmed-article:12691153 | pubmed:meshHeading | pubmed-meshheading:12691153... | lld:pubmed |
| pubmed-article:12691153 | pubmed:meshHeading | pubmed-meshheading:12691153... | lld:pubmed |
| pubmed-article:12691153 | pubmed:meshHeading | pubmed-meshheading:12691153... | lld:pubmed |
| pubmed-article:12691153 | pubmed:meshHeading | pubmed-meshheading:12691153... | lld:pubmed |
| pubmed-article:12691153 | pubmed:meshHeading | pubmed-meshheading:12691153... | lld:pubmed |
| pubmed-article:12691153 | pubmed:meshHeading | pubmed-meshheading:12691153... | lld:pubmed |
| pubmed-article:12691153 | pubmed:meshHeading | pubmed-meshheading:12691153... | lld:pubmed |
| pubmed-article:12691153 | pubmed:meshHeading | pubmed-meshheading:12691153... | lld:pubmed |
| pubmed-article:12691153 | pubmed:meshHeading | pubmed-meshheading:12691153... | lld:pubmed |
| pubmed-article:12691153 | pubmed:meshHeading | pubmed-meshheading:12691153... | lld:pubmed |
| pubmed-article:12691153 | pubmed:meshHeading | pubmed-meshheading:12691153... | lld:pubmed |
| pubmed-article:12691153 | pubmed:meshHeading | pubmed-meshheading:12691153... | lld:pubmed |
| pubmed-article:12691153 | pubmed:meshHeading | pubmed-meshheading:12691153... | lld:pubmed |
| pubmed-article:12691153 | pubmed:meshHeading | pubmed-meshheading:12691153... | lld:pubmed |
| pubmed-article:12691153 | pubmed:meshHeading | pubmed-meshheading:12691153... | lld:pubmed |
| pubmed-article:12691153 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12691153 | pubmed:articleTitle | HIV-testing and newly-diagnosed malignant lymphomas. The SAKK 96/90 registration study. | lld:pubmed |
| pubmed-article:12691153 | pubmed:affiliation | Fachbereich Onkologie-Hämatologie, Kantonsspital, CH-9007 St. Gallen, Switzerland. | lld:pubmed |
| pubmed-article:12691153 | pubmed:publicationType | Journal Article | lld:pubmed |
